

# **ERS 2012 Preview: QVA-149-LABA/LAMA FDC well Positioned to Take a Share in the Second Line and Third Line Setting for Treatment of COPD**

<https://marketpublishers.com/r/E44DBBCEF8FEN.html>

Date: August 2012

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: E44DBBCEF8FEN

## **Abstracts**

Novartis announced positive clinical data of QVA-149 from fifth and final successful pivotal clinical study result (SPARK) from IGNITE program on August 30th, 2012. The fixed dose LABA and LAMA combination-QVA149 met the primary end point in reducing the overall rate of exacerbations in COPD patients as compared to NVA237 / Seebri and Spiriva. Looking at cumulative data from all existing trials (ENLIGHTEN, ILLUMINATE, SPARK, and SHINE), QVA149 has clearly demonstrated that it is superior to existing treatment in patients refractory to once daily Spiriva. About 25-30% of Spiriva (LAMA) prescriptions have LABA's as co-prescribed drugs. QVA149 would provide the convenience of single therapy and once approved should cannibalize sales of Spiriva, twice daily LABA's and to some extent Advair. Pfizer alliance agreement on Spiriva as such is terminating in 2014 in the US and 2012-2013 in the EU and hence any market share loss would be immaterial from Pfizer perspective. The LABA/LAMA FDC will also impact to some extent the share of Advair, as about 30-35% of Spiriva prescriptions have Advair as a co-prescription. The data from ILLUMINATE study reinforce the superior efficacy QVA149 over Seretide/Advair. We forecast \$4 billion in market potential for LABA/LAMA FDC. GSK's fixed dose combination of Vilanterol (Once daily LABA) and Umeclidinium bromide (LAMA) to be launched around the same time would as well compete for a share.

## I would like to order

Product name: ERS 2012 Preview: QVA-149-LABA/LAMA FDC well Positioned to Take a Share in the Second Line and Third Line Setting for Treatment of COPD

Product link: <https://marketpublishers.com/r/E44DBBCEF8FEN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E44DBBCEF8FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

